In contrast , studies using pancreatic, breast, colon, and glioma cell lines [24–26] have shown that the downregulation of SRPK1 results in sensitivity to cisplatin-induced cell death, indicating that SRPK1 is a cisplatin resistance-related gene. This evidence concerns the gene SRPK1 and central nervous system cancer.